Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer cocktail shows promise in early human trial

NCT ID NCT04417465

Completed Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug works. The study is now complete, and results will help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ABBV-CLS-579 (oral capsule), PD-1 inhibitor (IV infusion), VEGFR TKI (oral tablet)
What this could lead to
If successful, this could point toward a new combination treatment option for certain advanced solid tumors like head and neck, lung, or kidney cancers.
What could go wrong
This is a very early (Phase 1) trial with only 101 participants, focused on safety and dosing. It is not designed to prove effectiveness, and many early cancer drugs do not advance to later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma nonpapillary renal cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CANCER

Contacts and locations

Locations

  • Carolina BioOncology Institute

    Huntersville, North Carolina, 28078, United States

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana, 46804, United States

  • Highlands Oncology Group Springdale

    Springdale, Arkansas, 72762, United States

  • Hopital Saint-Andre

    Bordeaux, 33000, France

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, 28050, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, 29010, Spain

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Kashiwa-Shi, Chiba, 277-8577, Japan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • The Chaim Sheba Medical Center

    Ramat Gan, 5262100, Israel

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • Wakayama Medical University Hospital

    Wakayama, Wakayama, 641-8510, Japan

  • Yale University

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.